A national precision cancer medicine implementation initiative for Finland

Authors

  • Katriina J. Jalkanen Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
  • Erika Alanne Turku University Hospital and FICAN West Cancer Centre, Turku, Finland
  • Sanna Iivanainen Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland
  • Okko-Sakari Kääriäinen Department of Oncology, Kuopio University Hospital, Kuopio, Finland
  • Minna Tanner TAYS Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland
  • Annika Auranen FICAN Mid, Central Finland Cancer Center, Tampere University and Tampere University Hospital, Tampere, Finland
  • Jussi Koivunen FICAN North, Northern Finland Cancer Center, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Timo K. Nykopp FICAN East, Eastern Finland Cancer Center, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
  • Pia Vihinen Turku University Hospital and FICAN West Cancer Centre, Turku, Finland
  • Mika Mustonen FICAN South, Southern Finland Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

DOI:

https://doi.org/10.2340/1651-226X.2024.32661

Keywords:

FINPROVE, DRUP-Like-Trials, Precision Medicine, PRIME-ROSE, PCM4EU

Downloads

Download data is not yet available.

References

Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–3825.

https://doi.org/10.1200/JCO.2015.61.5997 DOI: https://doi.org/10.1200/JCO.2015.61.5997

Andre F, Filleron T, Kamal M, Mosele F, Amedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022 Oct;610(7931):343–348.

https://doi.org/10.1038/s41586-022-05068-3 DOI: https://doi.org/10.1038/s41586-022-05068-3

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127–131.

https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x

van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, et al. Patients with biallelic BRCA1/2 inactivation respond to Olaparib treatment across histologic tumor types. Clin Cancer Res. 2021 Nov 15;27(22):6106–6114.

https://doi.org/10.1158/1078-0432.CCR-21-1104 DOI: https://doi.org/10.1158/1078-0432.CCR-21-1104

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022 May 14;20(1):225.

https://doi.org/10.1186/s12967-022-03432-5. Erratum in: J Transl Med. 2022 Jul 15;20(1):317. DOI: https://doi.org/10.1186/s12967-022-03432-5

Aldea M, Friboulet L, Apcher S, Jaulin F, Mosele F, Sourisseau T, et al. Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? ESMO Open. 2023 Oct;8(5):101642.

https://doi.org/10.1016/j.esmoop.2023.101642 DOI: https://doi.org/10.1016/j.esmoop.2023.101642

Downloads

Published

2024-05-23

How to Cite

Jalkanen, K. J., Alanne, E., Iivanainen, S., Kääriäinen, O.-S., Tanner, M., Auranen, A., Koivunen, J., Nykopp, T. K., Vihinen, P., & Mustonen, M. (2024). A national precision cancer medicine implementation initiative for Finland. Acta Oncologica, 63(1), 395–397. https://doi.org/10.2340/1651-226X.2024.32661

Issue

Vol. 63 (2024): Acta Oncologica

Section

Letter

Categories

License

Copyright (c) 2023 Katriina J. Jalkanen, Erika Alanne, Sanna Iivanainen, Okko-Sakari Kääriäinen, Minna Tanner, Annika Auranen, Jussi Koivunen, Timo K. Nykopp, Pia Vihinen, Mika Mustonen

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Funding data